# Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)

> **NCT04790916** · PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 2 (actual)

## Conditions studied

- Autoimmune Hepatitis
- Autoimmune Chronic Hepatitis

## Interventions

- **DRUG:** RO7049665
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04790916
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-19
- **Primary completion:** 2021-11-18
- **Final completion:** 2021-11-18
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** A lack of efficacy was seen with RO7049665 in a study of ulcerative colitis. This reduces the likelihood that the drug is effective in autoimmune hepatitis.
- **Last updated:** 2023-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04790916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04790916, "Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04790916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*